Utilization of Impella RP Flex for Right Ventricular Recovery in Cardiogenic Shock: A Single‐Center Experience
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31726 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Ioana Dumitru und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Advanced Heart Failure and Cardiac Transplant, Tampa General Hospital, University of South Florida, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Shock, Cardiogenic, Heart-Assist Devices, Ventricular Function, Right, Heart Failure. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Right ventricular failure (RVF) in patients with cardiogenic shock (CS) is associated with increased mortality. Mechanical circulatory support with Impella RP Flex may improve survival, but expert opinion is inconsistent due to lack of established best practices. We explore the impact of Impella RP Flex in treating patients with RVF.
Methods
In this single‐center, retrospective study, patients with RVF or biventricular failure treated with Impella RP Flex from December 2022 to March 2024 were reviewed. Clinical data included CS etiology, diagnostic laboratory values, and hemodynamics. Patient‐oriented outcomes were duration of Impella RP Flex support, survival rate, and 30‐day heart failure (HF) readmission rate. Secondary outcomes included incidence of complications.
Results
Twenty‐two SCAI stage D (72.7%) and E (27.3%) patients with RVF were implanted with Impella RP Flex, either alone or in combination with a left ventricular assist device (LVAD). The average duration of Impella RP Flex support was 6.6 (1, 14) days, and the overall mortality rate was 31.8% ( n = 7/22). Among survivors, four received orthotopic heart transplant, one received durable LVAD support, and 10 recovered to discharge. Vasopressors ( n = 17) and inotropes ( n = 17) were initiated in most patients before device support. Incidence of 30‐day HF readmission was 20% ( n = 3/15), and 68.2% ( n = 15/22) of patients required inpatient hemodialysis. Hemodynamics improved post‐Impella RP Flex implant, though hemolysis occurred in 86.4% ( n = 19/22) of patients, and bleeding requiring transfusion occurred in 63.6% ( n = 14/22).
Conclusions
Impella RP Flex may provide a treatment option for patients with CS and RVF who require inotropic or vasopressor support when used with careful attention to procedural technique and individualized risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Advanced Heart Failure and Cardiac Transplant, Tampa General Hospital, University of South Florida, Tampa, Florida, USA.
- Alabama College of Osteopathic Medicine, Dothan, Alabama, USA.
- University of South Florida, Tampa, Florida, USA.
ORCID-Profile: Ioana Dumitru
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Dumitru, I., DeWolf, J., Sevillano, M., Schnell, L., Bezerra, H., & Rinde-Hoffman, D. (2025). Utilization of Impella RP Flex for Right Ventricular Recovery in Cardiogenic Shock: A Single‐Center Experience. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31726
Vancouver
Dumitru I, DeWolf J, Sevillano M, Schnell L, Bezerra H, Rinde-Hoffman D. Utilization of Impella RP Flex for Right Ventricular Recovery in Cardiogenic Shock: A Single‐Center Experience. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31726
BibTeX
@article{Dumitru2025,
author = {Dumitru, Ioana and DeWolf, Jonathan and Sevillano, Maria and Schnell, Leeandra and Bezerra, Hiram and Rinde-Hoffman, Debbie},
title = {Utilization of Impella RP Flex for Right Ventricular Recovery in Cardiogenic Shock: A Single‐Center Experience},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31726}
}
EUVIMED